Science & Technology
Understanding disease to develop new cell-targeted approaches to care.
Biozipcode, Inc. conducts research and development into difficult-to-treat diseases, including diabetes. We look beyond symptom management to the cells and biological mechanisms that may sustain these conditions.
At the heart of our R&D are “diabetes stem cell research”, which examines abnormal hematopoietic stem cells thought to contribute to persistent diabetes and its complications, and “Biozipcode™ cell-targeting technology”, which selectively recognizes specific cells and tissues.
We aim to understand cells that may sustain disease, detect their altered states, and deliver treatments to the cells that need them. By connecting basic research with the development of diagnostic and therapeutic technologies, we hope to enable new approaches to care.
Science & Technology Links
We are developing new diagnostic and therapeutic technologies for difficult-to-treat diseases, built on diabetes stem cell research and Biozipcode™ cell-targeting technology.
We study abnormal hematopoietic stem cells thought to contribute to persistent diabetes and its complications, and investigate how their properties relate to disease.
We are researching new therapeutic approaches aimed at complete diabetes remission by targeting abnormal cells considered to be diabetes stem cells.
Biozipcode™ is a cell-targeting platform that identifies short peptide sequences recognizing specific cells and tissues for potential diagnostic and drug-delivery applications.
We aim to combine Biozipcode™ with drugs, genes, or nucleic acids to deliver therapeutic agents selectively to target cells.
Academic Collaboration Overview
Turning university research into technologies that can reach society.
New diagnostic and therapeutic approaches require expertise across medicine, life sciences, information science, clinical care, manufacturing, regulatory affairs, and intellectual property.
Through joint research with universities and research institutions, Biozipcode, Inc. aims to develop findings from basic research into reproducible technologies for diagnosis, treatment, and drug discovery.
Since 2026, we have conducted joint research with the industry–academia joint research department established at Kyoto University’s Graduate School of Medicine and Faculty of Medicine, the Department of Biocommunication Development. This work focuses on cell-targeted therapy. We are expanding partnerships with universities, healthcare institutions, and companies in Japan and abroad to bring research findings into practical use.
Academic Collaboration Overview
Through joint research with universities and research institutions, we aim to turn basic research findings into diagnostic and therapeutic technologies that can benefit society.
Through joint research with Kyoto University’s Graduate School of Medicine and Faculty of Medicine, we study difficult-to-treat diseases using cell-targeting technology.
We conduct basic and applied research with universities, research institutions, and healthcare organizations in Japan and abroad, drawing on their complementary expertise.
Pipeline Overview
Turning research findings into practical diagnostic and therapeutic technologies.
Biozipcode, Inc. aims to develop findings from basic research into diagnostic technologies, therapeutic candidates, cell-targeted drug candidates, and medical materials that can be put to practical use.
In diabetes, our R&D focuses on therapeutic candidates aimed at complete remission, biomarkers associated with diabetes stem cells, and cell-targeted drug candidates using Biozipcode™.
We also aim to apply Biozipcode™ cell-recognition technology to cancer-cell targeting and tissue regeneration. For each program, we are working toward development stages spanning basic and preclinical research, clinical application, and commercialization.
Pipeline Overview
Our R&D programs span diabetes, cancer, and tissue regeneration, including therapeutic candidates, biomarkers, and cell-targeted drug candidates.
We are investigating a therapeutic candidate aimed at complete remission of diabetes, with benefits that persist after treatment ends, by addressing mechanisms that sustain the disease.
We aim to measure cells and signals associated with diabetes stem cells for potential use in disease assessment, patient stratification, and monitoring treatment response.
We are developing investigational approaches that combine Biozipcode™ sequences recognizing diabetes stem cells with therapeutic molecules to act selectively on target cells.
We are studying investigational approaches that use Biozipcode™ sequences recognizing cancer cells to deliver anticancer drugs or genes to target cells.
We aim to develop medical technologies that combine cell-guiding peptides with biomaterials to support wound healing and tissue regeneration.
Research Achievements
Building on decades of research to advance future care.
Research into diabetes, hematopoietic stem cells, bone marrow-derived cells, diabetic complications, and regenerative medicine has developed over more than 20 years.
Published in journals in Japan and abroad, this work forms the scientific foundation of Biozipcode, Inc.’s current R&D. It includes studies of abnormal cells associated with persistent diabetes and research on complete remission in STZ-induced diabetic mice.
Alongside publications and conference presentations, we aim to protect findings through patents and other intellectual property, and develop them into new diagnostic and therapeutic technologies and joint development programs.
Research Achievements
Explore publications, patents, and conference presentations from years of research into diabetes, hematopoietic stem cells, cell targeting, and related fields.
Explore key publications on diabetes stem cells, diabetic complications, and complete remission research that underpin our R&D.
Explore our intellectual property work in diabetes treatment, diagnostics, abnormal stem cells, and Biozipcode™ to help bring research findings into practical use.
Explore Biozipcode research and activities through research videos, conference presentations, lectures, and seminars.
